Your session is about to expire
← Back to Search
Device
A Phase I Feasibility Study of an Intracortical Visual Prosthesis (ICVP) for People With Blindness (ICVP Trial)
N/A
Waitlist Available
Led By Philip R Troyk, PhD
Research Sponsored by Illinois Institute of Technology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from two-weeks post-op to end of device use, up to 3 years.
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if tiny wireless devices implanted in the brain can help blind people see by sending electrical signals to the brain's vision area.
Eligible Conditions
- Optic Neuropathy
- Vision loss
- Eye Injury
- Retinitis pigmentosa
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from two-weeks post-op to end of device use, up to 3 years.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from two-weeks post-op to end of device use, up to 3 years.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To test the safety of the WFMA-based cortical interface.
Secondary study objectives
To test the efficacy of the WFMA-based cortical interface
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: WFMA Cortical Visual Prosthesis Single-arm StudyExperimental Treatment1 Intervention
The WFMA is an electronic device that is implanted in the cortical vision processing regions of the brain to produce artificial vision.
Find a Location
Who is running the clinical trial?
Rush University Medical CenterOTHER
436 Previous Clinical Trials
249,247 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,332 Previous Clinical Trials
14,874,895 Total Patients Enrolled
University of ChicagoOTHER
1,057 Previous Clinical Trials
763,626 Total Patients Enrolled